Philadelphia gene therapy company Spirovant Sciences changed owners twice in 2019— including being acquired by Sumitomo Dainippon Pharma of Japan last week as part of

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it has completed the procedure related

The article in the Philadelphia Business Journal features how Spirovant is developing two gene therapies to treat, and potentially cure, cystic fibrosis.

Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading Japanese pharmaceutical company, and Roivant Sciences Ltd., a technology-enabled healthcare company, today announced that they have